Artiva Biotherapeutics names new Chief Medical Officer

Published 08/04/2025, 21:14
Artiva Biotherapeutics names new Chief Medical Officer

SAN DIEGO - Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company with a market capitalization of approximately $81 million, announced today the appointment of Dr. Subhashis Banerjee as its new Chief Medical Officer. According to InvestingPro analysis, the company appears undervalued based on its Fair Value metrics, despite facing significant challenges with a 72% decline in stock price over the past year. Dr. Banerjee, an experienced rheumatologist and immunologist, brings over twenty years of clinical development experience to the company, which focuses on cell therapies for autoimmune diseases and cancers.

Dr. Banerjee's career includes key positions at Bristol Myers Squibb (BMS) and VYNE Therapeutics, Inc., where he contributed to the development and regulatory approval of several well-known therapies for immune-mediated inflammatory conditions. His expertise is expected to advance Artiva's lead program, AlloNK®, targeting B-cell driven autoimmune diseases. For detailed analysis of Artiva's potential and comprehensive financial metrics, investors can access the full company research report on InvestingPro, which covers over 1,400 US stocks with expert insights and actionable intelligence.

The company's CEO, Dr. Fred Aslan, expressed confidence in Dr. Banerjee's ability to steer AlloNK® through late-stage development, highlighting the potential of the therapy to provide long-term treatment options for autoimmune diseases with an accessible and safe profile for broad use in community settings.

Dr. Banerjee's appointment is part of Artiva's broader initiative to strengthen its development team with seasoned professionals. This team includes recent hires such as David Moriarty, Ph.D., as SVP of Clinical Operations, Benjamin Dewees as SVP of Regulatory Affairs, and Feng Xu as SVP of Biometrics, all bringing extensive experience in their respective fields.

AlloNK® is currently in clinical trials for the treatment of systemic lupus erythematosus, with and without lupus nephritis, and is also being evaluated in a basket trial for multiple autoimmune indications. Artiva's pipeline also features CAR-NK candidates targeting various cancers.

Dr. Thorsten Graef, the outgoing Chief Medical Officer, will continue to support Artiva as a strategic advisor, contributing to the company's ongoing AlloNK oncology program.

Artiva was founded in 2019 and operates out of San Diego, California, with a strategic partnership granting exclusive worldwide rights to NK cell manufacturing technology and programs from GC Cell, a leading healthcare company in the Republic of Korea. InvestingPro data shows the company maintains a strong liquidity position with a current ratio of 15.39, holding more cash than debt on its balance sheet, though it's currently experiencing rapid cash burn as it advances its clinical programs.

This article is based on a press release statement, and the information provided is subject to the risks and uncertainties outlined by Artiva Biotherapeutics in its SEC filings.

In other recent news, Artiva Biotherapeutics has been the subject of notable developments. Artiva's lead product candidate, AlloNK, is currently undergoing clinical trials for systemic lupus erythematosus and other autoimmune conditions. The company anticipates releasing initial data from at least one autoimmune trial involving AlloNK in the first half of 2025. Analyst firm H.C. Wainwright reaffirmed its Buy rating with a $20 price target for Artiva, highlighting the potential of AlloNK's cost-effective and scalable treatment approach. Meanwhile, Cantor Fitzgerald adjusted its price target for Artiva shares to $20 from $23, maintaining an Overweight rating despite cautious investor sentiment toward the cell therapy sector. On the corporate side, Artiva appointed Daniel Baker, Ph.D., as a new member of its Board of Directors and Clinical Strategy Committee, alongside other key industry veterans. Dr. Baker brings extensive experience from his tenure at Johnson & Johnson and other prominent roles in the biotech industry. These strategic appointments are part of Artiva's efforts to enhance its governance and strategic planning as it advances its portfolio of cellular therapies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.